Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA, acting through HHS, has approved updated labels for three estradiol transdermal patches, removing outdated black box warnings about breast cancer, cardiovascular disease, and probable dementia. This builds on a February 2026 labeling overhaul for six other menopausal hormone therapy products. The agency is also working to boost manufacturing capacity to improve access to MHT across the U.S.
The FDA, operating under HHS, has approved updated safety labels for three more estradiol transdermal patches used in menopausal hormone therapy (MHT). The move removes what officials are calling "outdated risk statements" from black box warnings — specifically those flagging risks of breast cancer, cardiovascular disease, and probable dementia — continuing a regulatory push that began in November 2025.
This latest action expands on a February 2026 decision in which the FDA revised labeling for six MHT products to better reflect current evidence on risk-benefit profiles. Since the FDA began engaging manufacturers in late 2025, 29 companies have submitted proposed label changes, and the agency says it's working "expeditiously" to process them. HHS also signaled efforts to accelerate manufacturing changes that could increase MHT supply and availability nationwide.
Key Takeaways:
Why it matters: For clinicians and patients, clearer and more evidence-based labeling could reduce hesitancy around prescribing and using MHT — a treatment that has long been underutilized due to decades-old safety concerns that modern research has largely reframed.
